• Cancer cachexia and cancer-associated thrombosis have not previously been mechanistically linked.
Essentials
• Cancer cachexia and cancer-associated thrombosis have not previously been mechanistically linked.
• We assessed thrombin generation and coagulation parameters in cachectic C26 tumor-bearing mice.
• C26 mice are hypercoagulable, partially corrected by blocking tumor derived interleukin-6.
• Coagulability and anti-inflammatory interventions may be clinically important in cancer cachexia.
Summary. Background: Cancer cachexia and cancer-associated thrombosis are potentially fatal outcomes of advanced cancer, which have not previously been mechanistically linked. The colon 26 (C26) carcinoma is a wellestablished mouse model of complications of advanced cancer cachexia, partially dependent on high levels of interleukin-6 (IL-6) produced by the tumor. Objectives: To assess if cancer cachexia altered the coagulation state and if this was attributable to tumor IL-6 production. Methods: In male BALB/c*DBA2 (F1 hybrid) mice with a C26 tumor we used modified calibrated automated thrombogram and fibrin generation (based on overall hemostatic potential) assays to assess the functional coagulation state, and also examined fibrinogen, erythrocyte sedimentation rate (ESR), platelet count, tissue factor pathway inhibitor (TFPI) and hepatic expression of coagulation factors by microarray. C26 mice were compared with non-cachectic NC26, pair-fed and sham control mice. IL-6 expression in C26 cells was knocked down by lentiviral shRNA constructs. Results: C26 mice with significant weight loss and highly elevated IL-6 had elevated thrombin generation, fibrinogen, ESR, platelets and TFPI compared with all control groups. Fibrin generation was elevated compared with pair-fed and sham controls but not compared with NC26 tumor mice. Hepatic expression of coagulation factors and fibrinolytic inhibitors was increased. Silencing IL-6 in the tumor significantly, but incompletely, attenuated the increased thrombin generation, fibrinogen and TFPI. Con
Introduction
Thrombosis is one of the most severe complications for patients with advanced cancer, with an increased risk of venous thrombosis of up to 28-fold depending on cancer type [1] . This high risk of potentially fatal thromboembolism is at least partially caused by prothrombotic factors generated by the tumors, can be exaggerated by cancer treatments and persists despite anticoagulation [2] [3] [4] . Detection of hemostatic risk factors is important for targeted treatment [5] [6] [7] , especially because the role of hemostasis in tumor growth and metastasis is bidirectional; elevated coagulation and platelets promote tumor growth, and the inhibition of coagulation can prevent tumor progression in animal models (reviewed in [8, 9] ). However, measurement of individual markers may not reflect the overall hemostatic balance, which can be assessed by global functional coagulation assays measuring thrombin and fibrin generation [10] [11] [12] . The use of in vivo models provides important insights into the role of hemostasis in cancer, but there is a paucity of functional coagulation data in mouse tumor models. The colon 26 (C26) carcinoma is a well-documented mouse model of complications of advanced cancer [13, 14] . The predominant feature of this model is development of cancer cachexia, the progressive loss of body mass that cannot be reversed by nutritional intake [15, 16] . We and others have shown that the C26 phenotype is dependent on the high levels of interleukin-6 (IL-6) produced by the tumor, a pro-inflammatory cytokine that is involved clinically in the pathogenesis of weight loss in various cancer types [17] . When mice were implanted with a C26 variant lacking IL-6, the tumors grew but the mice did not become cachectic [18] . IL-6 signaling pathways are activated in brown and white adipose tissue [19] and skeletal muscle [20] , and IL-6 knockdown targeting the tumor cells [18] and other IL-6 inhibitory agents [21] suppress cachexia in tumor-bearing mice. One of the diverse effects of IL-6 is its promotion of coagulation [22] , raising the question of a link between these two clinical features of advanced cancer, cachexia and hypercoagulability. Previous studies using this model have found that fibrinogen, an acute phase reactant that is also a central player in coagulation, is elevated in the C26 model [20] , and that plasminogen activator, essential for the breakdown of clots through fibrinolysis, is also increased in mice bearing the C26 tumor [23] . However, to the best of our knowledge, no investigation of thrombin or fibrin generation has been carried out in C26 tumor-bearing mice or its relationship to cachexia.
We therefore assessed the coagulation state in the C26 model of cancer cachexia using functional coagulation assays in cachectic (C26) and non-cachectic (NC26) mice and investigated the effects of blocking tumor IL-6 production. We report that thrombin generation and other coagulation parameters are elevated in cachectic but not in non-cachectic tumor-bearing animals, potentially mediated through increased hepatic expression of coagulation factors, and that silencing tumor IL-6 production partially corrects cachexia-related hypercoagulability.
Methods

Animal studies
The cachexia-inducing colon 26 cells (C26) are a murine colon carcinoma and were kindly provided by AMGEN (Thousand Oaks, CA, USA) [24] . The non-cachectic variant of the C26 tumor was sourced from Tohoku University (Sendai, Japan). C26 cells were grown and maintained in RPMI medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Invitrogen), 100 lg mL À1 penicillin and 100 U mL À1 streptomycin (Invitrogen) in 5% CO 2 . Pathogen-free, 10-12-week-old male BALB/ c*DBA2 (F1 Hybrid) mice were from ARC, Perth (Australia). Animals were housed at an ambient temperature of 22°C under a 12-h light cycle (lights on 06.00 to 18.00 h). Colon 26 cells were washed thrice in serum-free RPMI-1640 medium; 10 6 cells suspended in 100 lL of the same were inoculated subcutaneously into the shaved right flanks of mice. Control mice were injected with 100 lL of RPMI-1640 medium containing antibiotics but no cells. Following engraftment, body weight, food intake and tumor dimensions were recorded daily. Tumor-bearing and free-fed control mice had ad libitum access to food. One group of control mice was pair-fed to match the progressive reduction in daily food intake of the cachectic C26 tumor-bearing group, by giving non-tumor-bearing control mice the food intake of corresponding C26 tumor-bearing animals. 
Blood collection and analysis
Mice were anesthetized with ketamine/xylazine and blood collected by cardiac puncture using a syringe preloaded with 50 lL citrate anticoagulant. The mice were then euthanized by cervical dislocation.
After collection, the volume of sodium citrate (0.109 M) (BD Biosciences, Franklin Lakes, NJ, USA) was adjusted to the exact ratio of 1 : 9 citrate to blood. The citrated blood was centrifuged at room temperature at 2500 9 g for 15 min, and the supernatant centrifuged again at 10 000 9 g for 5 min. The plasma was stored at À80°C in aliquots. Erythrocyte sedimentation rate (ESR) was assayed in 100-mm, 100-lL capillaries (Drummond Microcaps, Drummond Scientific Company, Broomall, PA, USA) filled with blood diluted with additional 0.109 M citrate to a final ratio of 1 : 4 citrate to blood, as in the Westergren method. Platelet counts were performed on a Sysmex micropore counter (Sysmex Corporation, Kobe, Japan).
Thrombin generation
The calibrated automated thrombogram (CAT) describes the potential of plasma to generate thrombin. A modified CAT was carried out as follows [25] . Plasmas were diluted 1 in 6 with HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, pH 7.35, stored at À20°C) plus 5 mg mL À1 bovine serum albumin (BSA). Modified thrombin generation was performed in a Fluoroskan Ascent fluorometer (Thermo Labsystems, Helsinki, Finland). Briefly, 40 lL of diluted plasma were dispensed into the wells of Immulon microplates 2HB from Thermo Labsystems containing 10 lL of calibrator or "PPP-Reagent LOW" (containing 1 pM human tissue factor). Thrombin generation was triggered by the automatic dispensing of 10 lL of FluCa reagent (thrombin fluorogenic substrate and calcium) at 37°C. Fluorescence was measured every 20 s over a 60-min period. All tests were performed in triplicate. Reagents were from Diagnostica Stago (Asin eres, France). The Thrombinoscope software program (Thrombinoscope BV, Maastricht, the Netherlands) was used to calculate the endogenous thrombin potential (ETP), which is the total thrombin generation potential expressed in arbitrary units (AU), the peak thrombin generation and the lagtime (time to start of thrombin generation).
To assess the contribution of endogenous circulating tissue factor (TF) to the thrombin generation results, TF-dependent thrombin generation was assessed in some experiments using a blocking antibody specific for mouse tissue factor (1H1, provided by Genentech, South San Francisco, CA, USA) [26] . Contact activation was inhibited with the addition of 4 lM corn trypsin inhibitor (Haematologic Technologies, Essex Junction, VT, USA) prior to 15 min incubation at room temperature with 100 lg mL À1 1H1 or IgG2a j isotype control (BioLegend, San Diego, CA, USA). To confirm that 1H1 inhibited TF activity under these conditions, thrombin generation was triggered without the addition of TF (4 lM phospholipids: 20 mol% phosphatidylserine, 20 mol % phosphatidylethanolamine and 60 mol% phosphatidylcholine, Avanti Polar Lipids, Alabaster, AL, USA). Thrombin generation was then carried out as above (using PPP low human TF trigger) in pooled mouse plasma samples.
Fibrin generation and fibrinolysis
A novel fibrin generation and fibrinolysis assay was developed and carried out as follows based on the overall hemostatic potential (OHP) assay [27] . Plasmas were diluted 1 in 2 with HEPES-buffered saline. Fibrin time curves were generated in microtiter plate wells at 37°C. tissue plasminogen activator (Actilyse, Boehringer Ingelheim, Ingelheim am Rhein, Germany). Automated absorption measurements were taken at 405 nm every minute for 60 min. Fibrin generation was calculated as the area under the fibrin generation curve in arbitrary units (AU) and fibrin delay was recorded as the time until fibrin generation began. Clot lysis time (CLT) was defined as the time between the mid-point of the clear-to-turbid transition and the turbid-to-clear transition of the fibrinolysis curve.
Liver microarray
Change in hepatic expression of coagulation-relevant factors was measured using Affymetrix gene microarrays. Liver tissue was isolated from three sham and three cachectic C26 mice and total RNA extracted using Trizol (Invitrogen) and the Pro200 homogenizer (Daintree Scientific, St Helens, TAS, Australia). RNA concentration was determined from the absorbance at 230, 260 and 280 nm using the Biophotometer (Eppendorf, Hamburg, Germany). Quality control of total RNA was confirmed using the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). The gene expression profile was determined by using the GeneChip Mouse Gene 1.0 ST Array by Affymetrix at the Ramaciotti Centre for Gene Function Analysis at the University of New South Wales (Sydney, Australia), consisting of 28 815 characterized genes, captured and processed with the GeneChip Operating System (Affymetrix, Santa Clara, CA, USA).
Array data were processed using standard pipelines (e.g. Limma R package [28] and GenePattern [29] ). Changes were considered significant where q < 0.05.
Western blotting
Plasma fibrinogen was assayed by western blot. Plasmas were diluted in Laemmli buffer, warmed to 37°C for 5 min and the equivalent of 0.04-0.1 lL plasma loaded per lane. Fibrinogen on blots was detected with polyclonal antibody A0080 (Dako Glostrup, Denmark), itself detected with a goat-anti-rabbit-HRP conjugate, visualized by enhanced chemiluminescence substrate (ECL) (ThermoFisher Scientific, Waltham, MA, USA or Bio-Rad, Hercules, CA, USA).
ELISAs
Tissue factor pathway inhibitor (TFPI) ELISA (Mouse TFPI Duoset, R&D Systems) was performed according to the manufacturer's instructions. Substrate Reagent and Stop Solution 2 N Sulfuric Acid were purchased from R&D Systems. Dilution of plasma samples was optimized to 1/500.
Interleukin 6 (IL-6) ELISA (Quantikine ELISA, Mouse IL-6 Immunoassay, R&D Systems) was performed according to the manufacturer's instructions. Dilution of plasma samples was optimized to 1/10.
Statistical analyses
Data were analyzed by one-way ANOVA with Fisher's Least Significant Difference (LSD) test. Significance was accepted at P < 0.05. Data are presented as mean AE standard deviation, unless otherwise stated.
Results
Increased thrombin and fibrin generation, TFPI, fibrinogen and platelet count in cachectic C26 tumor mice
The colon 26 carcinoma produced significant weight loss (16.22 AE 2.6%) over 2 weeks, in agreement with the previous body of published work (Fig. 1A) [15, 16] . A variant of the C26 carcinoma did not produce cachexia (NC26 tumor). Mice pair-fed with the cachectic group also had significant weight loss (14.92 AE 1.7%), indicating the anorectic component of the cachexia.
Modified thrombin generation demonstrated hypercoagulability of cachectic C26 animals, illustrated by sample curves (Fig. 1B) .
and pair-fed (131.6 AE 29.2 AU, n = 10, P < 0.0001) animals (Fig. 1C) . Peak thrombin generation was also significantly elevated in cachectic C26 mice compared with all control groups (Fig. 1D) .
Measurement of fibrin generation demonstrated hypercoagulability of a subset of tumor-bearing animals. Overall coagulation measured by area under the curve (Fig. 1E ) was higher in cachectic (3.6 AE 1.4 AU, n = 5) than sham controls (0.16 AE 0.02 AU, n = 2, P = 0.0026) and pair-fed (0.5 AE 0.2 AU, n = 3, P = 0.0022) animals, but no different to NC26 tumor mice (2.8 AE 1.1 AU, n = 5, P = 0.245). Clot lysis time was higher in sham controls than in tumor-bearing mice (Fig. 1F) . The thrombin and fibrin generation results indicate global hypercoagulability in cachectic tumor-bearing animals but paradoxically also a consistent increase in thrombin generation lagtime (Fig. 1G ) and fibrin generation delay (Fig. 1H) . These increased delays might be explained by elevated levels of circulating tissue factor pathway inhibitor (TFPI) in cachectic mice compared with other groups (Fig. 2A) .
To further elucidate the coagulation changes in cachectic C26 mice, other coagulation-relevant parameters were assessed in these groups. Circulating fibrinogen, as assessed by western blot, was substantially elevated in cachectic C26 mice, but only modestly in NC26 tumor mice (Fig. 2B) . This was also reflected in erythrocyte sedimentation rates (ESR), which were significantly elevated in cachectic C26 mice but only slightly so in NC26 tumor mice (Fig. 2C) . Platelet counts were similarly elevated in cachectic C26 mice compared with all control groups (Fig. 2D) . Animals pair-fed with the cachectic C26 mice were not different from healthy control mice in any of these parameters.
To determine whether circulating endogenous tissue factor contributed to the elevated thrombin generation in cachectic C26 mice, we performed the TF-triggered thrombin generation assay in the presence of a mouse tissue factor blocking antibody (1H1) with no cross-reactivity to human TF [26, 30] . We confirmed in preliminary experiments that 1H1 inhibited thrombin generation in mouse plasma in the absence of exogenous TF (data not shown). Comparison of pooled plasma (2-3 mice for each) of sham, cachectic C26 or non-cachectic NC26 samples showed that the changes in human TF-triggered thrombin generation were unaffected by blocking endogenous murine tissue factor (Fig. 3) , indicating that circulating TF does not contribute to the changes in thrombin generation observed between the experimental groups.
Cachectic C26 carcinoma increases transcription of coagulation factors in the liver
We identified changes in hepatic coagulation and fibrinolysis gene expression associated with cancer cachexia (Table 1) . Microarray analysis was performed on liver mRNA from mice inoculated with the C26 tumor and compared to livers from sham control mice. mRNA expression of all three fibrinogen chains was up-regulated between 2 and 5-fold. Coagulation factors II, V, VII, VIII, IX, X, XII and XIIIA1 (the active subunit of XIII) exhibited up to 2-fold increases in mRNA, whereas factor XIIIb was reduced. Interestingly, the multiple coagulation factor deficiency protein 2 (Mfcd2), involved in transport of factors V and VIII from endoplasmic reticulum to Golgi was also increased. Most anticoagulant factors, including antithrombin, were not affected, but tissue factor pathway inhibitor (Tfpi) mRNA was increased 1.39-fold. Interestingly, thrombopoietin expression in the liver was elevated, consistent with increased circulating platelets. There was no change in the liver in factors III (tissue factor) or XI (data not shown).
Fibrinolytic promoters tissue plasminogen activator and urokinase plasminogen activator were unchanged, although plasminogen (Plg) mRNA was increased 1.51-fold (Table 1) . On the other hand, fibrinolytic inhibitor mRNAs were noticeably up-regulated, including thrombin-activatable fibrinolysis inhibitor (TAFI; Cpb2 3.75), plasminogen activator inhibitor-1 (PAI-1; Serpine1 1.47), alpha2-antiplasmin (Serpinf2 1.78) and alpha2-macroglobulin (A2m mRNA microarray 73).
Elevated thrombin generation in cachectic C26 carcinoma is partially dependent on IL-6
As IL-6 was greatly elevated in the cachectic C26 mice (228.0 AE 92.2 pg mL À1 ) while being not detectable in the control and pair-fed groups and just detectable in the NC26 tumor mice (Fig. 4A) , an IL-6-silenced C26 tumor model was developed to investigate whether the coagulation changes observed in the cachectic animals were dependent on tumor-derived IL-6. Because previous work demonstrated that the source of culprit IL-6 is the tumor [18] , C26 cells were treated with an IL-6 silencing shRNA or a vector control. Circulating IL-6 levels were confirmed to be elevated in C26 (164.5 AE 49.3 pg mL À1 , P = 0.0002 vs. sham) and vector control animals (272.5 AE 90.9 pg mL À1 , P < 0.0001 vs. sham), but low in the IL-6 silenced tumor animals (3.8 AE 3.2 pg mL À1 , P = 0.919 vs. sham) (Fig. 4B ). Animals inoculated with the IL-6-silenced cells developed tumors of the same size as the cachectic mice (day 14 tumor area 120 AE 11 mm 2 vs. 135 AE 25 mm 2 ), but did not lose body weight overall, compared with mice bearing C26 tumor treated with the vector control cells, which developed cachexia to the same extent as C26 alone, with a weight loss of 16.8 AE 0.8% (Fig. 5A) .
Modified thrombin generation demonstrated hypercoagulability of all tumor groups compared with sham controls, illustrated by sample curves (Fig. 5B) . ETP was significantly elevated in the cachectic C26 (589.8 AE 36.34 AU, n = 8, P < 0.0001 vs. sham) and C26/vector control groups (525.8 AE 21.32 AU, n = 5, P < 0.0001 vs. sham) compared with the sham controls (263.5 AE 16.41 AU, n = 6), but this was attenuated (although still higher than the sham controls) in mice bearing the IL-6-silenced tumor (418.8 AE 46.94 AU, n = 6, P < 0.0001 vs. C26, P < 0.0001 vs. sham) (Fig. 5C ). Similar trends were observed for peak thrombin generation and lagtime ( Fig. 5D and E) . TFPI (Fig. 5F ) was also significantly attenuated by knocking down IL-6 in the tumor compared with the vector NC26 + IgG2a NC26 + 1H1 Fig. 3 . Circulating endogenous tissue factor (TF) does not contribute to thrombin generation. In a pool of (A) sham (n = 3), (B) cachectic C26 (n = 2) and (C) non-cachectic NC26 (n = 2) mouse plasma samples, blocking with mouse TF antibody 1H1 did not affect thrombin generation under the conditions used in our assay. [Color figure can be viewed at wileyonlinelibrary.com]. control, corresponding to the reduction in thrombin lagtime. ESR (Fig. 5G) and fibrinogen ( Fig. 5H and Fig. S1 ) were markedly increased in the cachectic C26 and C26/ vector control groups, but attenuated with the IL-6-silenced tumor.
Discussion
Cancer cachexia and cancer-associated thrombosis are both potentially fatal outcomes of advanced cancer, but they have not previously been mechanistically linked. We show here hypercoagulability in mice bearing a tumor variant causing cachexia, and that this is partly attributable to high levels of IL-6 production by the tumor and likely mediated through increased hepatic expression of coagulation factors and fibrinolytic inhibitors. We tested thrombin generation in the plasmas of tumor-bearing mice and found a global increase compared with both sham-engrafted controls and pair-fed mice (tumor-free mice pair-fed with the C26 mice and losing weight to a similar extent). Elevated thrombin generation has been clinically associated with increased risk of venous thromboembolism in cancer patients [31] . In mice bearing a non-cachectic, low IL-6 variant of the tumor (NC26 tumor), we found that thrombin generation was not elevated above the sham control. Further, mice bearing the same tumor variant with IL-6 expression silenced in the tumor did not lose weight, and in plasma from these mice, elevated thrombin generation was attenuated (although not completely). This suggests that the elevated inflammatory state was at least partly responsible for the observed hypercoagulability.
Similarly, we found fibrin generation increased in cachectic mice, but this was not exclusive to the cachectic group, as NC26 tumor mice also had increased capacity for fibrin generation. This finding was partially explained by fibrinogen levels, which were increased in the NC26 mice but were higher in the cachectic C26 group, and this was consistent with a high ESR (a measurement of acute phase response that is greatly affected by fibrinogen levels [32] ) in the C26 mice but not the NC26 group.
Global assays integrate the effects of concurrent and opposing changes in multiple parts of the hemostatic system and provide information about the mechanisms underlying the overall hypercoagulable state. Although the initial rate of thrombin and fibrin generation in C26 mice is impaired compared with normal mice we can conclude that other changes in the hemostatic system result in an overall hypercoagulable state. We have shown here that these approaches to global coagulation are effective methods for assessment of hypercoagulable states in mice. The fibrin generation and fibrinolysis assay for analysis of mouse plasma was a novel method developed for this study, based on the overall hemostatic potential assay [27] .
We identified that the platelet count was increased in C26 but not NC26 mice. In cancer patients thrombocytosis is associated with advanced cancer (reviewed in [9] ) and high platelet counts are clinically associated with increased risk of venous thromboembolism (reviewed in [6] ). As well as providing coagulation effectors and a surface for localization of the coagulation process, a previous mouse tumor model showed that platelets directly promoted tumor growth [33] . This suggests that the in vivo prediction of thrombosis risk will be complicated in these models, and will require integration of both global coagulation and platelet-mediated pathways.
Fibrinolysis, measured by clot lysis time, was not impaired in tumor-bearing animals, and this could be because of imbalanced changes in levels of plasminogen activator [23] and related activators and inhibitors. Another unexpected finding of this work was the lengthened thrombin lagtime and fibrin delay observed in the cachectic C26 mice. Our observation that TFPI levels were elevated in the cancer cachexia group offers a potential explanation for this phenomenon. TFPI is a serine protease inhibitor that acts on the TF/FVIIa complex, inhibiting downstream activation, as well as directly inhibiting FXa. The thrombin generation measured by the CAT is the downstream burst occurring at the final 'propagation' stage of hemostasis [34] , meaning that the levels and interactions of multiple coagulation factors and inhibitors contribute to the length of time taken for the burst to occur. In human plasma under the same assay conditions, circulating TFPI negatively correlates with thrombin generation parameters [35] , and under similar assay conditions with a higher trigger concentration of TF, TFPI concentrations directly correlate with thrombin lagtime without affecting ETP [36] .
Circulating tumor and host-derived tissue factor (TF) has been identified as an important link between cancer and thrombosis [37, 38] and TF expression has been reported in colon 26 cell lines [39] . We therefore examined the contribution of circulating TF activity to our results and found that specifically blocking tissue factor in plasma from sham control, cachectic and non-cachectic mice had no effect on thrombin generation under our conditions, suggesting the observed hypercoagulability was secondary to other factors. To further investigate the mechanistic link between the tumor and hypercoagulable state, we report the results of a microarray approach to assess expression differences between the livers of cachectic C26 and sham control mice. In the cachectic C26 mice there was an overall pattern of up-regulation of coagulation factors and fibrinolytic inhibitors, including fibrinogen, factors II, V, VII, VIII, IX, X, XII and XIIIa1, thrombopoietin, TAFI, PAI-1, alpha2-antiplasmin and alpha2 macroglobulin. Elevated circulating levels of most of these factors have been previously clinically linked to thrombosis [40] [41] [42] and contribute to increased thrombin generation [43] . The direct cause of the increased expression of coagulation factors in this mouse model is unknown, although given the high levels of IL-6 in these mice, these findings support an effect of IL-6 on coagulation via the liver.
IL-6 is a major contributing factor to cachexia in the C26 model [20, 21, 44] and is additionally a promoter of coagulation [22] . The non-cachectic tumor control (NC26) in our study resulted in circulating IL-6 levels comparable to sham controls, and additionally had normal levels of thrombin generation. Therefore, to directly investigate the role of IL-6 we silenced IL-6 in the C26 tumor cells and found this did not alter tumor growth but did prevent cachexia. Global hypercoagulability was partially dependent on C26 tumor-derived IL-6, as demonstrated by the incomplete attenuation of elevated thrombin generation in mice bearing IL-6 silenced C26 tumors. Fibrinogen levels and ESR were also incompletely attenuated by IL-6 silencing, and TFPI was also reduced, corresponding with a reduction in thrombin lagtime. Recent and current clinical trials are evaluating the use of IL-6 or IL-6 receptor blockers such as siltuximab or tocilizumab in the treatment of cancer, and the outcomes include reduction of cancer-associated cachexia [45] [46] [47] and reduction of cancer-associated thrombocytosis [48] . In other contexts, IL-6 blocking as treatment for rheumatoid arthritis reduces circulating fibrinogen and D-dimer [49, 50] , raising the possibility of IL-6-targeting treatment as a potential avenue for reduction of thrombotic risk in cancer.
In conclusion, we have shown here that cachectic C26 tumor-bearing mice have elevated fibrinogen and platelets and increased global coagulability as assessed by thrombin and fibrin generation. This was not because of the presence of the tumor alone, as mice bearing a non-cachectic, low IL-6 variant tumor had thrombin generation levels equivalent to non-tumor-bearing (sham) controls and circulating fibrinogen levels that were increased but to a lesser extent than was evident in the plasma from cachectic animals. The effect was also not because of weight loss, as mice pair-fed with the cachectic C26 mice lost weight but did not significantly differ from sham controls in any marker of coagulation. As blocking IL-6 production partially corrects this hypercoagulability, these data lend support to a mechanistic link between inflammatory cytokines and paraneoplastic conditions causing thrombosis. 
